首页>投融资
Foresight Diagnostics
B轮(B2)
Foresight Diagnostics Inc is a diagnostic and testing company that developed novel liquid biopsy testing platform to detect early-stage tumors.In April 2023, Foresight Diagnostics Inc closed an oversubscribed Series B financing round of $58.75 million
基本信息
-
公司全称Foresight Diagnostics Inc
-
类型分子诊断产品开发商
-
产业领域器械/设备、试剂/耗材
-
公司人数15人以下
-
地址AURORA COLORADO; US;
-
联系电话
-
邮箱contact@foresight-dx.com
-
成立时间2020-01-01
投融资
-
2024-07-30B轮(B2)3300万美元University of Colorado Healthcare Innovation FundStanford UniversityAgent CapitalPear VenturesBluebird VenturesCivilization VenturesForesite Capital
-
2023-04-27B轮(B1)5875万美元Bluebird VenturesPear VenturesUniversity of Colorado Healthcare Innovation FundAgent CapitalForesite CapitalCivilization VenturesStanford University
-
2021-06-02A轮1250万美元Pear VenturesCivilization VenturesBluebird Ventures
相关投融资企业
IPO后其他轮次
ONWARD Inc (previously known as GTX Medical) is a MedTech company focused on the development and commercialization of innovative therapies to accelerate and augment functional recovery of people with spinal cord injury and to improve their quality of life.In June 2022, ONWARD Inc received a grant from the European Commission of EUR 3.6 million to support the enhancement of an innovative brain-computer interface technology for restoring mobility and upper-limb function in people with spinal cord injury
未公开
ATANIS Biotech是一家生物技术公司的经营者，旨在简化和改善目前过敏诊断的护理标准。该公司提供了一种新颖的基于功能细胞的检测方法，简化了过敏的诊断，并可以预测治疗的治疗成功率，为客户提供了一种可靠的功能性过敏筛查工具。
收并购
Omixon是一家全球性的移植诊断公司，其使命是为组织相容性实验室提供创新技术，以改善移植结果。Omixon总部位于匈牙利布达佩斯，在美国、巴西和荷兰设有分支机构，为全球60多家实验室提供服务。2014年，Omixon率先成功推出基于ngs的HLA分型试剂盒和软件，将基于ngs的HLA基因分型产品Holotype HLA和HLA Twin软件推向市场。Omixon Twin提供最准确的高分辨率HLA基因分型，并在全球60多个实验室中使用。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息